Literature DB >> 2952486

Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.

J H Laragh.   

Abstract

Overactivity of the renin-angiotensin-aldosterone system occurs in the syndrome of congestive cardiac failure. Aldosterone overactivity is crucially involved in maintaining the oedematous state as evidenced by its often complete correction by adrenalectomy, or by aldosterone antagonists, in both experimental and clinical heart failure. The hyperaldosteronism of heart failure can also be attacked by angiotensin-converting enzyme (ACE) inhibition, which not only blocks the angiotensin drive to aldosterone, but also unloads the heart by blocking renin-angiotensin-mediated vasoconstriction. Accordingly, ACE inhibition alone, if continued in full dosage, can often reduce or obviate the need for daily thiazide diuretic therapy. This specific, two-pronged therapy with fewer side effects emerges as a primary strategy for the treatment of congestive heart failure. To learn more about why and how the renin system becomes involved in heart failure, the renal functional abnormalities have been re-examined. The effects of sodium administration on central haemodynamics and on the activity of the renin system have als been studied. This research has led to a consideration of the role of atrial natriuretic hormone in this pathophysiological interplay. The study recharacterized renal haemodynamic patterns and indicated that in congestive heart failure there is a disproportionate diversion of blood away from the kidneys because of afferent vasoconstriction. However, the glomerular filtration rate is maintained by concurrent efferent arteriolar constriction, expressed by a rising filtration fraction. As heart failure advances, the filtration fraction can no longer rise. At this point, the glomerular filtration rate becomes flow-dependent and falls commensurately with the declining cardiac output. These intrarenal patterns may be mediated in part by increased intrarenal renin activity resulting from heart failure and diuretic therapy. A further study of the abnormal renin system activity operating in heart failure has shown it to be very sensitive to dietary salt intake. Thus, consuming modest amounts of salt (100 mEq/day) was sufficient to markedly suppress renin and aldosterone values. However, since peripheral resistance was not changed, another non-renin, sodium-related mechanism must take over to sustain increased arterial constriction. The fact that captopril challenge evoked no response before and a large response after sodium depletion supports this concept. preliminary data suggest that atrial natriuretic hormone may also be important in congestive heart failure by opposing renin system activity at 4 sites.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2952486     DOI: 10.2165/00003495-198600325-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

1.  PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES.

Authors:  R P AMES; A J BORKOWSKI; A M SICINSKI; J H LARAGH
Journal:  J Clin Invest       Date:  1965-07       Impact factor: 14.808

2.  Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog.

Authors:  H E DE WARDENER; I H MILLS; W F CLAPHAM; C J HAYTER
Journal:  Clin Sci       Date:  1961-10       Impact factor: 6.124

Review 3.  Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis.

Authors:  J H Laragh
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

4.  Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

Authors:  H R Brunner; H Gavras; J H Laragh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

5.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

6.  Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure.

Authors:  R J Cody; A B Covit; G L Schaer; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1983-04       Impact factor: 24.094

7.  Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.

Authors:  T Maack; D N Marion; M J Camargo; H D Kleinert; J H Laragh; E D Vaughan; S A Atlas
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

8.  Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility.

Authors:  H D Kleinert; T Maack; S A Atlas; A Januszewicz; J E Sealey; J H Laragh
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

9.  Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats.

Authors:  H Gavras; H B Brunner; E D Vaughan; J H Laragh
Journal:  Science       Date:  1973-06-29       Impact factor: 47.728

10.  Atrial natriuretic factor: a hormone produced by the heart.

Authors:  A J de Bold
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

View more
  4 in total

Review 1.  Angiotensin converting enzyme inhibitors.

Authors:  A Breckenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-27

2.  Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function.

Authors:  J Nolan; A D Flapan; S Capewell; T M MacDonald; J M Neilson; D J Ewing
Journal:  Br Heart J       Date:  1992-06

Review 3.  Peripheral factors in the management of congestive heart failure.

Authors:  L Demopoulos; T H LeJemtel
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

Review 4.  The use of angiotensin-converting enzyme inhibitors in congestive heart failure.

Authors:  J L Rouleau; C Juneau; J de Champlain
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.